BC Innovations | Jun 28, 2018
Distillery Therapeutics


INDICATION: Breast cancer In vitro , cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two compounds...
BC Innovations | Jan 25, 2018
Targets & Mechanisms

Unexpected combinations

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical...
BC Extra | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine , Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are --...
BC Week In Review | May 26, 2017
Company News

BioAtla, Beijing Sinobioway expand CAB deal

BioAtla LLC (San Diego, Calif.) and Beijing Sinobioway Group Ltd. (Beijing, China) added five products from BioAtla's Conditionally Active Biologic (CAB) platform to a 2015 deal granting Sinobioway exclusive rights to develop and commercialize similar...
BC Innovations | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
BC Innovations | Nov 2, 2016
Distillery Therapeutics


INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest inhibiting AXL could help treat ovarian cancer. In patients, high tumor expression of AXL correlated with poor overall survival. In two human ovarian cancer...
Items per page:
1 - 6 of 6